Correlation Between Semi-Quantitative (18)F-FDG PET/CT Parameters and Ki-67 Expression in Small Cell Lung Cancer

Overview

Journal Nucl Med Mol Imaging

Publisher Springer

Date 2016 Mar 5

PMID 26941856

Citations 10

Authors

Soyeon Park

Eunsub Lee

Seunghong Rhee

Jaehyuk Cho

Sunju Choi

Sinae Lee

Jae Seon Eo

Kisoo Pahk

Jae Gol Choe

Sungeun Kim

Affiliations

Soon will be listed here.

Abstract

Purpose: The aim of this study was to evaluate the relationship between semiquantitative parameters on (18)F-FDG PET/CT including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) and the expression level of Ki-67 in small-cell lung cancer (SCLC).

Methods: Ninety-four consecutive patients with SCLC were enrolled in this study. They underwent (18)F-FDG PET/CT for initial evaluation of SCLC, and we measured SUVmax, avgSUVmean, MTVsum, and TLGtotal on (18)F-FDG PET/CT images. The protein expression of Ki-67 was examined by immunohistochemical staining.

Results: Significant correlations were found between the MTVsum and Ki-67 labeling index (r = 0.254, p = 0.014) and the TLGtotal and Ki-67 labeling index (r = 0.239, p = 0.020). No correlation was found between the SUVmax and Ki-67 labeling index (r = 0.116, p = 0.264) and the avgSUVmean and Ki-67 labeling index (r = 0.031, p = 0.770). Dividing the Ki-67 expression level into three categories, it was suggested that increasing Ki-67 expression level caused a stepwise increase in the MTVsum and TLGtotal. (p = 0.028 and 0.039, respectively), but not the SUVmax and avgSUVmean (p = 0.526 and 0.729, respectively).

Conclusion: In conclusion, the volume-based parameters of (18)F-FDG PET/CT correlate with immunohistochemical staining of Ki-67 in SCLC. Measurement of the MTVsum and TLGtotal by (18)F-FDG PET/CT might be a simple, noninvasive, and useful method to determine the proliferative potential of cancer cells.

Citing Articles

Editorial: Opportunities for PET imaging for the identification, staging, and monitoring of cancers.

Sun J, Sun Z, Zhang L Front Oncol. 2023; 13:1135928.

PMID: 36761979 PMC: 9904280. DOI: 10.3389/fonc.2023.1135928.

Application of diffusion kurtosis imaging and F-FDG PET in evaluating the subtype, stage and proliferation status of non-small cell lung cancer.

Feng P, Shao Z, Dong B, Fang T, Huang Z, Li Z Front Oncol. 2022; 12:989131.

PMID: 36248958 PMC: 9562703. DOI: 10.3389/fonc.2022.989131.

Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki-67/CD31.

Zhong N, Zhuang W, Huang Q, Wang Q, Jin W J Cell Mol Med. 2021; 25(21):10039-10048.

PMID: 34590406 PMC: 8572765. DOI: 10.1111/jcmm.16926.

Clinical Significance of Quantitative FDG PET/CT Parameters in Non-Small Cell Lung Cancer Patients.

Shadmehr M, Khosravi A, Abbasi Dezfouli A, Bakhshayesh-Karam M, Jamaati H, Doroudinia A Tanaffos. 2021; 19(3):186-194.

PMID: 33815538 PMC: 8008410.

Primary tumor standardized uptake value (SUVmax) measured on F-FDG PET/CT and mixed NSCLC components predict survival in surgical-resected combined small-cell lung cancer.

Hui Z, Wei F, Ren H, Xu W, Ren X J Cancer Res Clin Oncol. 2020; 146(10):2595-2605.

PMID: 32494919 PMC: 7467962. DOI: 10.1007/s00432-020-03240-8.

References

Li R, Heydon K, Hammond M, Grignon D, Roach 3rd M, Wolkov H . Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res. 2004; 10(12 Pt 1):4118-24. DOI: 10.1158/1078-0432.CCR-1052-03. View

Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert A . Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 2004; 91(12):2018-25. PMC: 2409786. DOI: 10.1038/sj.bjc.6602233. View

Tabata K, Tanaka T, Hayashi T, Hori T, Nunomura S, Yonezawa S . Ki-67 is a strong prognostic marker of non-small cell lung cancer when tissue heterogeneity is considered. BMC Clin Pathol. 2014; 14:23. PMC: 4032346. DOI: 10.1186/1472-6890-14-23. View

Arbiser Z, Arbiser J, Cohen C, Gal A . Neuroendocrine lung tumors: grade correlates with proliferation but not angiogenesis. Mod Pathol. 2001; 14(12):1195-9. DOI: 10.1038/modpathol.3880459. View

Alexandrakis M, Passam F, Kyriakou D, Dambaki K, Niniraki M, Stathopoulos E . Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol. 2004; 27(1):8-13. DOI: 10.1097/01.coc.0000045810.91816.41. View

Indinnimeo M, Cicchini C, Stazi A, Limiti M, Ghini C, Mingazzini P . Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. J Exp Clin Cancer Res. 2001; 19(4):471-5. View

Yang W, Zhang Y, Fu Z, Yu J, Sun X, Mu D . Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2010; 37(7):1291-9. DOI: 10.1007/s00259-010-1412-6. View

Inwald E, Klinkhammer-Schalke M, Hofstadter F, Zeman F, Koller M, Gerstenhauer M . Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013; 139(2):539-52. PMC: 3669503. DOI: 10.1007/s10549-013-2560-8. View

Zlotta A, Schulman C . Biological markers in superficial bladder tumors and their prognostic significance. Urol Clin North Am. 2000; 27(1):179-89, xi-xii. DOI: 10.1016/s0094-0143(05)70246-9. View

10.

Xie P, Yue J, Zhao H, Sun X, Kong L, Fu Z . Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2009; 136(6):883-9. DOI: 10.1007/s00432-009-0729-7. View

11.

Kaira K, Serizawa M, Koh Y, Takahashi T, Hanaoka H, Oriuchi N . Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer. 2012; 48(8):1244-54. DOI: 10.1016/j.ejca.2012.01.016. View

12.

Li Y, Lin Q, Zhao L, Wang L, Sun L, Dai M . Pre-treatment metabolic tumor volume and total lesion glycolysis are useful prognostic factors for esophageal squamous cell cancer patients. Asian Pac J Cancer Prev. 2014; 15(3):1369-73. DOI: 10.7314/apjcp.2014.15.3.1369. View

13.

Rohren E, Turkington T, Coleman R . Clinical applications of PET in oncology. Radiology. 2004; 231(2):305-32. DOI: 10.1148/radiol.2312021185. View

14.

Buck A, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G . Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003; 44(9):1426-31. View

15.

Stuart-Harris R, Caldas C, Pinder S, Pharoah P . Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 2008; 17(4):323-34. DOI: 10.1016/j.breast.2008.02.002. View

16.

Han B, Lin S, Yu L, Wang R, Wang Y . Correlation of ¹⁸F-FDG PET activity with expressions of survivin, Ki67, and CD34 in non-small-cell lung cancer. Nucl Med Commun. 2009; 30(11):831-7. DOI: 10.1097/MNM.0b013e32832dcfc4. View

17.

Cummings T, Provenzale J, Hunter S, Friedman A, Klintworth G, Bigner S . Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathol. 2000; 99(5):563-70. DOI: 10.1007/s004010051161. View

18.

Lee H, Hyun S, Lee K, Kim B, Kim J, Shim Y . Volume-based parameter of 18)F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol. 2010; 17(10):2787-94. DOI: 10.1245/s10434-010-1107-z. View

19.

Johnson B, Janne P . Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin North Am. 2004; 18(2):309-22. DOI: 10.1016/j.hoc.2003.12.008. View

20.

Yap C, Czernin J, Fishbein M, Cameron R, Schiepers C, Phelps M . Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006; 129(2):393-401. DOI: 10.1378/chest.129.2.393. View